NCT04614779View on ClinicalTrials.gov

Long-term Clinical Study of CN128 in Thalassemia Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

September 30, 2020

Primary Completion Date

August 18, 2022

Study Completion Date

August 18, 2022

Conditions
ThalassemiaIron Overload
Interventions
DRUG

CN128 Tablets

Iron chelator, oral tablets

Trial Locations (1)

530021

The First Affiliated Hospital Of Guangxi Medical University, Nanning

All Listed Sponsors
lead

Hangzhou Zede Pharma-Tech Co., Ltd.

OTHER

NCT04614779 - Long-term Clinical Study of CN128 in Thalassemia Patients | Biotech Hunter | Biotech Hunter